Risk management in the treatment of malignant gliomas with BCNU wafer implants

Zentralblatt fur Neurochirurgie

Volumn 71, Issue 4, 2010, Pages 199-206

  Giese, A ^a   Bock, H C ^a   Kantelhardt, S R ^a   Rohde, V ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

BCNU wafer; carmustine; glioblastoma; glioma; local chemotherapy

Indexed keywords

CARMUSTINE; CEFAZOLIN; DEXAMETHASONE; PLACEBO; POLYMER; TEMOZOLOMIDE;

BIODEGRADABLE IMPLANT; BLOOD TOXICITY; BRAIN EDEMA; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CRANIOTOMY; DEEP VEIN THROMBOSIS; DNA DAMAGE; DRUG DOSE REDUCTION; EDEMA; FOLLOW UP; GLIOMA; HUMAN; IMPLANTATION; INTRAOPERATIVE PERIOD; LEUKOPENIA; LONG TERM CARE; LUNG EMBOLISM; NONHUMAN; PATIENT SELECTION; POSTOPERATIVE CARE; POSTOPERATIVE INFECTION; REVIEW; RISK MANAGEMENT; SEIZURE; SIDE EFFECT; SURGICAL TECHNIQUE; THROMBOCYTOPENIA;

ABSORBABLE IMPLANTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CARMUSTINE; COMBINED MODALITY THERAPY; DRUG IMPLANTS; GLIOMA; HUMANS; INTRAOPERATIVE CARE; PATIENT SELECTION; POSTOPERATIVE CARE; RISK MANAGEMENT;

EID: 78649275684     PISSN: 00444251     EISSN: 14389746     Source Type: Journal    
DOI: 10.1055/s-0029-1242775     Document Type: Review

References (44)

1. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers, edition v1.2008. National Comprehensive Cancer Network 2008 Available at http://www.nccn.org/professionals/physician-gls/pdf/cns.pdf
2. Final appraisal determination carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma. National Institute for Health and Clinical Excellence 2007 Available at http://www.nice.org.uk/ nicemedia/pdf/glioma-carmustine-fad.pdf
3. Gliadel « Wafer [prescribing information]. MGI PHARMA, Bloomington, MN, USA 2006.
4. Gliadel Wafer [summary of product characteristics]. West Sussex, UK 2006
5. MGI PHARMA. Gliadel Wafer: Heath Care Professionals Available at http://www.gliadel.com/hcp/default.aspx [Last accessed 21 February 2008]
6. MGI PHARMA. How to Use GLIADEL« Wafer 2007 Available at http://www.gliadel.com/hcp/about/how.aspx [Last accessed 6 May 2008]
7. Barker FG, 2nd. Efficacy of prophylactic antibiotics against meningitis after craniotomy: a meta-analysis. Neurosurgery 2007 60 887-894 discussion 887894
8. Bertin ML MA, Barnett G, Gordon S. Risk factors for surgical site infection after 1,3- bis (2-chlorethyl)-1-nitrosurea (BCNU) Gliadel wafer implantation for glioblastoma. Infect Control Hosp Epidemiol 2000 21 (Abstract) 144
9. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-Brain Tumor Treatment Group. Lancet 1995 345 1008-1012
10. Brem H, Tamargo RJ, Olivi A, et al. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J Neurosurg 1994 80 283-290
11. Darakchiev BJ, Albright RE, Breneman JC, et al. Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme. J Neurosurg 2008 108 236-242
12. Engelhard HH. The role of interstitial BCNU chemotherapy in the treatment of malignant glioma. Surg Neurol 2000 53 458-464
13. Erickson LC, Laurent G, Sharkey NA, et al. DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells. Nature 1980 288 727-729
14. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000 343 1350-1354
15. Fung LK, Ewend MG, Sills A, et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 1998 58 672-684
16. Gallego JM, Barcia JA, Barcia-Marino C. Fatal outcome related to carmustine implants in glioblastoma multiforme. Acta Neurochir (Wien) 2007 149 261-265 discussion 265
17. Gibson NW, Hartley J, La France RJ, et al. Differential cytotoxicity and DNA-damaging effects produced in human cells of the Mer+ and Mer- phenotypes by a series of alkyltriazenylimidazoles. Carcinogenesis 1986 7 259-265 (Pubitemid 17136427)
18. Giese A, Kucinski T, Knopp U, et al. Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma. J Neurooncol 2004 66 351-360
19. Golden GA, Meldorf M, Group PS. Number of wafers used in a cohort of 322 patients implanted with Gliadel wafer. Neuro-Oncol 2004 6 (Abstract) 375
20. Gururangan S, Cokgor L, Rich JN, et al. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro-Oncol 2001 3 246-250
21. Hammond LA, Eckardt JR, Kuhn JG, et al. A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. Clin Cancer Res 2004 10 1645-1656
22. Hammoud DA, Belden CJ, Ho AC, et al. The surgical bed after BCNU polymer wafer placement for recurrent glioma: serial assessment on CT and MR imaging. AJR Am J Roentgenol 2003 180 1469-1475
23. Hughes MA, Parisi M, Grossman S, et al. Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection. Int J Radiat Oncol Biol Phys 2005 62 1423-1426
24. Jones NS, Becker DG. Advances in the management of CSF leaks. BMJ 2001 322 122-123
25. McGirt MJ, Than KD, Weingart JD, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 2009 110 583-588
26. McGovern PC, Lautenbach E, Brennan PJ, et al. Risk factors for postcraniotomy surgical site infection after 1,3-bis (2-chloroethyl)-1- nitrosourea (Gliadel) wafer placement. Clin Infect Dis 2003 36 759-765
27. Menei P, Metellus P, Loiseau H, et al. Biodegradable carmustine impregnated wafers (Gliadel): the French experience Neuro-Oncol, (EANO) 2008 (Abstract): 1138
28. Miliaras G, Tsitsopoulos PP, Markoula S, et al. Multifocal glioblastoma with remote cutaneous metastasis: a case report and review of the literature. Cent Eur Neurosurg 2009 70 (1) 39-42
29. Mitchell RB, Dolan ME. Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol 1993 32 59-63
30. Pan E, Mitchell SB, Tsai JS. A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J Neurooncol 2008 88 353-357
31. Plowman J, Waud WR, Koutsoukos AD, et al. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 1994 54 3793-3799
32. Prager JM, Grenier Y, Cozzens JW, et al. Serial CT and MR imaging of carmustine wafers. AJNR Am J Neuroradiol 2000 21 119-123
33. Psaras T, Will BE, Schoeber W, et al. Quantitative assessment of postoperative blood collection in brain tumor surgery under valproate medication. Zentralbl Neurochir 2008 69 (4) 165-169
34. Raizer JJ, Malkin MG, Kleber M, et al. Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. Neuro-Oncol 2004 6 247-252
35. Raslan A, Bhardwaj A. Medical management of cerebral edema. Neurosurg Focus 2007 22 E12
36. Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. Curr Med Res Opin 2008 24 (11): 3239-3257
37. Schröter S, Halatsch ME, Behnke-Mursch J, et al. Self-help activities of brain tumour patients and their relatives. Cent Eur Neurosurg 2009 70 (1) 21-26
38. Sampath P, Brem H. Implantable slow-release chemotherapeutic polymers for the treatment of malignant brain tumors. Cancer Control 1998 5 130-137
39. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005 352 987-996
40. Tamargo RJ, Epstein JI, Reinhard CS, Chasin M, Brem H. Brain biocompatibility of a biodegradable, controlled-release polymer in rats. J Biomed Mater Res 1989 23 253-266 (Pubitemid 19042070)
41. Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997 41 44-48 discussion 4849
42. van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 2007 6 421-430
43. Weber EL, Goebel EA. Cerebral edema associated with Gliadel wafers: two case studies. Neuro-Oncol 2005 7 84-89
44. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncol 2003 5 79-88